nejm glp 1 Discovery of GLP-1–Based Drugs for the Treatment of Obesity NEJM: Once-Weekly Semaglutide in Adults

A major new clinical trial is putting a spotlight on one of the biggest conversations in medicine right now: what happens when GLP-1based therapy is brought into psoriatic arthritis care

This case highlights the need for gradual insulin tapering and close monitoring while transitioning from insulin therapy to GIP/GLP-1 receptor agonists.

Contains aGLP-1 receptoragonist used in weight management

Compounded drugs are not regulatory approved, despite having similar active ingredients

Is microdosing semaglutide or tirzepatide safe

Given these considerations, the therapeutic approach in older patients with T2D is complex, particularly in those who have functional dependence, frailty, dementia, or who are at end-of-life